Skip to main content
Ahmad S. Halwani
( out of 34 reviews )

Ahmad S. Halwani, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
801-585-2626
  • Dr. Ahmad Halwani is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies in the Department of Internal Medicine at the University of Utah and a clinical investigator at the Huntsman Cancer Institute (HCI). He is also a staff physician and clinical researcher at the George E Whalen Veterans Health Administration (VHA) in Salt Lake City. Dr. Halwani’s practice at Huntsman Cancer Institute focuses on lymphoid malignancies, specifically Lymphoma and Chronic Lymphocytic Leukemia (CLL). Dr. Halwani was also responsible for leading an effort to establish the first lymphoid malignancy focused clinic at the George E Whalen VHA where Veterans with Lymphoma and CLL can receive sub-specialty focused care.


    For questions regarding Dr. Halwani's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at www.huntsmancancer.org or (801) 585-6906.

    Board Certification

    American Board of Internal Medicine (Sub: Medical Oncology)
    Educational Commission for Foreign Medical Graduates

    Patient Rating

    4.7 /5
    ( out of 34 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 25, 2023
    HUNTSMAN CANCER CENTER

    Dr Halwani is always a pleasure to work with and does a good job of reviewing and explaining the results of my blood tests. I appreciate the time he spends reviewing my health history.

    August 20, 2023
    HUNTSMAN CANCER CENTER

    Dr Halawani is very kind and very thorough

    July 24, 2023
    HUNTSMAN CANCER CENTER

    He is the best

    July 15, 2023
    HUNTSMAN CANCER CENTER

    Dr. Halwani always greets with a happy personality and a very caring attitude. He listens very carefully and explains in a manner I understand

    March 06, 2023
    HUNTSMAN CANCER CENTER

    Dr. Halwani is a very caring doctor who has handled my CLL with utmost professionalism

    February 20, 2023
    HUNTSMAN CANCER CENTER

    Very good. Explains everything so that my family and I know whats happening and in a way we understand.

    February 11, 2023
    HUNTSMAN CANCER CENTER

    A compassionate and energetic oncologist, a great communicator, and a leader in lymphoma treatment and research. I am very grateful I was referred to Dr. Halwani. His Fellow who works with him is excellent as well and getting very good training.

    December 12, 2022
    HUNTSMAN CANCER CENTER

    I really liked Dr Halwani. Hes knowledgeable and caring and was always ready to move on the the next step in my treatment when it was needed.

    October 05, 2022
    HUNTSMAN CANCER CENTER

    Doctor was rude and lecturing us about why were there when we were simply doing what our primary physician told us to to follow-up. The doctor lectured us for quite a while repeating that in all essence we were wasting his time. To clarify this was the doctor and NOT the nurse practitioner who came in first. She was phenomenal. He very simply could have told us that he had no cancer concerns at this time and that there is no need to follow up with the Huntsman unless something changes. Was a terrible experience with him.

  • Dr. Ahmad Halwani is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies in the Department of Internal Medicine at the University of Utah and a clinical investigator at the Huntsman Cancer Institute (HCI). He is also a staff physician and clinical researcher at the George E Whalen Veterans Health Administration (VHA) in Salt Lake City. Dr. Halwani’s practice at Huntsman Cancer Institute focuses on lymphoid malignancies, specifically Lymphoma and Chronic Lymphocytic Leukemia (CLL). Dr. Halwani was also responsible for leading an effort to establish the first lymphoid malignancy focused clinic at the George E Whalen VHA where Veterans with Lymphoma and CLL can receive sub-specialty focused care.


    For questions regarding Dr. Halwani's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at http://www.huntsmancancer.org or (801) 585-6906.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine (Sub: Medical Oncology)
    Educational Commission for Foreign Medical Graduates

    Education history

    Fellowship Medical Oncology - University of Iowa Hospitals & Clinics Fellow
    Allergy and Immunology - University of Iowa Hospitals & Clinics Fellow
    Residency Internal Medicine - University of Iowa Hospitals & Clinics Resident
    Medicine - American University of Beirut M.D.
    Undergraduate Biology with High Distinction - American University of Beirut B.S.

    Selected Publications

    Journal Article

    1. Chien HC, Morreall D, Patil V, Rasmussen KM, Yong C, Li C, Passey DG, Burningham Z, Sauer BC, Halwani AS (2021). Treatment Patterns and Outcomes in a Nationwide Cohort of Older and Younger Veterans with Waldenström Macroglobulinemia, 2006-2019. Cancers (Basel), 13(7). (Read full article)
    2. Li C, Patil V, Rasmussen KM, Yong C, Chien HC, Morreall D, Humpherys J, Sauer BC, Burningham Z, Halwani AS (2021). Predicting Survival in Veterans with Follicular Lymphoma Using Structured Electronic Health Record Information and Machine Learning. Int J Environ Res Public Health, 18(5). (Read full article)
    3. Chien HC, Morreall D, Patil V, Rasmussen KM, Li C, Yong CM, Burningham Z, Masaquel A, Halloran M, De Long-Sieg E, Schulz M, Sauer BC, Halwani AS (2020). Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma. Future Oncol, 17(4), 411-422. (Read full article)
    4. Passey DG, Healy R, Qualls J, Halwani A, Sauer BC (2020). Pharmacist-led collaborative medication management programs for oral antineoplastic therapies: A systematic literature review. J Am Pharm Assoc (2003), 61(3), e7-e18. (Read full article)
    5. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H (2020). NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Netw, 18(11), 1460-1467. (Read full article)
    6. Halwani AS, Rasmussen KM, Patil V, Morreall D, Li C, Yong C, Burningham Z, Dawson K, Masaquel A, Henderson K, DeLong-Sieg E, Sauer BC (2020). Maintenance rituximab in Veterans with follicular lymphoma. Cancer Med, 9(20), 7537-7547. (Read full article)
    7. Richter Lagha R, Burningham Z, Sauer BC, Leng J, Peters C, Huynh T, Patel S, Halwani AS, Kramer BJ (2020). Usability Testing a Potentially Inappropriate Medication Dashboard: A Core Component of the Dashboard Development Process. Appl Clin Inform, 11(4), 528-534. (Read full article)
    8. Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH (2020). NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Netw, 18(5), 522-536. (Read full article)
    9. Rasmussen KM, Patil V, Burningham Z, Yong C, Sauer BC, Halwani AS (2020). Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration. Fed Pract, 37(Suppl 2), S44-S49. (Read full article)
    10. Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, Gupta S, Narayanan S, Lin SW, Carroll S, Mhatre SK, Graff JN, Dreicer R, Sauer BC (2019). Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol, 38(1), 1.e1-1.e10. (Read full article)
    11. Walsh JA, Pei S, Penmetsa GK, Sauer BC, Patil V, Walker JH, Clewell J, Douglas KM, Clegg DO, Cannon GW, Halwani A (2019). Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis. J Manag Care Spec Pharm, 25(11), 1218-1228. (Read full article)
    12. Burningham Z, Chen W, Sauer BC, Richter Lagha R, Hansen J, Huynh T, Patel S, Leng J, Halwani A, Kramer BJ (2019). VA Geriatric Scholars Program's impact on prescribing potentially inappropriate medications. Am J Manag Care, 25(9), 425-430. (Read full article)
    13. Peters CB, Hansen JL, Halwani A, Cho ME, Leng J, Huynh T, Burningham Z, Caloyeras J, Matsuda T, Sauer BC (2019). Validation of Algorithms Used to Identify Red Blood Cell Transfusion Related Admissions in Veteran Patients with End Stage Renal Disease. EGEMS (Wash DC), 7(1), 23. (Read full article)
    14. Elkeeb D, Hopkins Z, Miles RR, Halwani A, Wada D (2019). Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review. Eur J Dermatol, 28(6), 809-817. (Read full article)
    15. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M, MAVORIC Investigators (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol, 19(9), 1192-1204. (Read full article)
    16. Burningham Z, Leng J, Peters CB, Huynh T, Halwani A, Rupper R, Hicken B, Sauer BC (2018). Predicting Psychiatric Hospitalizations among Elderly Veterans with a History of Mental Health Disease. EGEMS (Wash DC), 6(1), 7. (Read full article)
    17. Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H (2018). NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. J Natl Compr Canc Netw, 16(2), 123-135. (Read full article)
    18. Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, Avigdor A, Halwani AS, Houot R, Marchand T, Dhedin N, Lescaut W, Thiebaut-Bertrand A, Franois S, Stamatoullas-Bastard A, Rohrlich PS, Labussire Wallet H, Castagna L, Santoro A, Bachanova V, Bresler SC, Srivastava A, Kim H, Pesek E, Chammas M, Reynolds C, Ho VT, Antin JH, Ritz J, Soiffer RJ, Armand P (2017). Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood, 129(10), 1380-1388. (Read full article)
    19. Vrontikis A, Carey J, Gilreath JA, Halwani A, Stephens DM, Sweetenham JW (2016). Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. Oncology (Williston Park), 30(11), 970-4, 980-1, C3. (Read full article)
    20. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J (2016). Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol, 34(23), 2698-704. (Read full article)
    21. McPherson JP, Vrontikis A, Sedillo C, Halwani AS, Gilreath JA (2016). Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions. Pharmacotherapy, 36(2), e8-e11. (Read full article)
    22. Colonna S, Halwani A, Ying J, Buys S, Sweeney C (2015). Women with breast cancer in the Veterans Health Administration: demographics, breast cancer characteristics, and trends. Med Care, 53(4 Suppl 1), S149-55. (Read full article)
    23. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med, 372(4), 311-9. (Read full article)
    24. Nelson SD, Lu CC, Teng CC, Leng J, Cannon GW, He T, Zeng Q, Halwani A, Sauer B (2015). The use of natural language processing of infusion notes to identify outpatient infusions. Pharmacoepidemiol Drug Saf, 24(1), 86-92. (Read full article)
    25. Ontiveros EP, Halwani A, Stunz LL, Kamberos N, Olivier AK, Janz S, Bishop GA (2014). A new model of LMP1-MYC interaction in B cell lymphoma. Leuk Lymphoma, 55(12), 2917-23. (Read full article)
    26. Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S (2013). Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochem Biophys Res Commun, 436(4), 660-5. (Read full article)
    27. Halwani AS, Link BK (2011). Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. Expert Rev Anticancer Ther, 11(3), 443-55. (Read full article)
    28. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ (2008). A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res, 14(20), 6697-703. (Read full article)

    Letter

    1. Chien HC, Morreall D, Patil V, Rasmussen KM, Yong CM, Li CY, Passey DG, Burningham Z, Sauer BC, Halwani AS (2021). Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019. [Letter to the editor]. Am J Hematol, 96(6), E184-E187. (Read full article)
    2. Laggis CW, Lamb A, Secrest AM, Ufkes N, Halwani AS, Tao R, Gaffney D, Miles RR, Florell SR, Wada D (2020). Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution. [Letter to the editor]. J Eur Acad Dermatol Venereol, 35(1), e42-e45. (Read full article)

    Abstract

    1. Kim YH, Bagot M, Eradat HA, Carson KR, Greer JP, Kim EJ, Kuzel T, Hughey LC, Poligone B, Lansigan F, Zinzani PL, Grandinetti LM, Procu P, Shustov AR, Korman NJ, Halwani A, Sokol L, Duvic M (01012014). Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab vs vorinostat in relapsed or refractory cutaneous t-cell lymphoma (CTCL). [Abstract]. J Clinical Oncology American Society of Clinicial Oncology annual meeting.
    2. Lesokhin A, Gutierrez M, Halwani A, Ansell SM, Armand P, Borrello I, Segota ZE, Cohen AD, Talpaz M, Cattry D, Turner T, Mezes M, Hartman C, Gupta A, Kim SY, Wigginton JM, Timmerman JM (01012014). A Phase 1 Dose Escalation Study Evaluating the Effects of Nivolumab (anti-PD-1; BMS-936558) in Patients with Select Relapsed or Refractory Hematologic Malignancies. [Abstract]. J Clinical Oncology American Society of Clinicial Oncology annual meeting.
    3. Halwani A, Stunz S, Hu L, Janz S, Bishop G (2010). A new mouse lymphoma model, the iMycEµ-LMP1 transgenic mouse, suggests collaboration of LMP1 and Myc in lymphomagenesis. Poster Presentation; University of Iowa Carver College of Medicine, College of Pharmacy, College of Public Health, Institute for Clinical and Translational Science and VA Health System Research Week. [Abstract].
    4. Halwani A, Ballas Z (2009). Progression of Selective IgM Deficiency to Common Variable Immunodeficiency. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting [Abstract]. 123(2, Supplement 1), S89.
    5. Halwani A (2008). Eczematous Rash, Elevated IgE & Recurrent Infections. Presented at the Clinical Immunology Society Primary Immunodeficiency Summer School. [Abstract].
    6. Halwani A, Ballas Z (2008). Delayed Recovery of T Cell Response Post Cyclosporin Therapy. Journal of Allergy and Clinical Immunology. Poster Presentation, AAAAI annual meeting. [Abstract]. 121(2, Supplement 1), S87.
    7. Halwani A, Gingrich R (2005). An Unusual Tonsillitis. American College of Physicians, Iowa Chapter, Associates Clinical Vignette Competition. [Abstract].
  • News & Podcasts